Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EBITDA (2022 - 2025)

Stoke Therapeutics has reported EBITDA over the past 4 years, most recently at -$57.8 million for Q4 2025.

  • Quarterly results put EBITDA at -$57.8 million for Q4 2025, down 435.58% from a year ago — trailing twelve months through Dec 2025 was -$6.2 million (up 93.05% YoY), and the annual figure for FY2025 was -$6.2 million, up 93.05%.
  • EBITDA for Q4 2025 was -$57.8 million at Stoke Therapeutics, down from -$38.0 million in the prior quarter.
  • Over the last five years, EBITDA for STOK hit a ceiling of $112.9 million in Q1 2025 and a floor of -$57.8 million in Q4 2025.
  • Median EBITDA over the past 4 years was -$25.5 million (2022), compared with a mean of -$18.8 million.
  • Peak annual rise in EBITDA hit 528.56% in 2025, while the deepest fall reached 435.58% in 2025.
  • Stoke Therapeutics' EBITDA stood at -$25.1 million in 2022, then fell by 6.8% to -$26.8 million in 2023, then skyrocketed by 59.76% to -$10.8 million in 2024, then tumbled by 435.58% to -$57.8 million in 2025.
  • The last three reported values for EBITDA were -$57.8 million (Q4 2025), -$38.0 million (Q3 2025), and -$23.3 million (Q2 2025) per Business Quant data.